Oxford University's ChAdOx1 BDBV vaccine targeting the Bundibugyo strain has moved into Phase‑1 human trials just 57 days after the outbreak was declared. India's Serum Institute rapidly manufactured 620,000 doses, supplying 4,000 for the trial.

Key Takeaways

  • Oxford‑backed ChAdOx1 BDBV vaccine begins Phase‑1 testing
  • Serum Institute of India produces 620,000 doses, provides 4,000 for trial
  • Vaccine development accelerated by $8.6 million CEPI partnership

Scientists at the Oxford Vaccine Group and the Pandemic Sciences Institute have developed a vaccine against the Bundibugyo strain of Ebola virus, and it has entered Phase‑1 clinical trials just 57 days after the outbreak was declared a public‑health emergency. The trial will enroll 50 healthy adults aged 18‑55 in Oxford, United Kingdom, to assess safety and immune‑response generation.

Scientific Platform

The candidate, named ChAdOx1 BDBV, uses the same chimpanzee adenovirus (ChAdOx) vector that powered the Oxford‑AstraZeneca COVID‑19 vaccine—an effort credited with saving more than six million lives in its first year. Leveraging this proven platform accelerates confidence that the new vaccine can elicit a robust protective response.

Serum Institute’s Critical Contribution

India’s Serum Institute of India (SII) stepped in to scale production at unprecedented speed. Within two weeks, the Pune‑based manufacturer produced and stockpiled roughly 620,000 investigational doses and supplied 4,000 doses for the Phase‑1 study. CEO Adar Poonawalla emphasized, “During outbreaks, speed, preparedness and global collaboration are essential to advancing vaccine candidates quickly and responsibly.”

Global Partnership and Future Trials

Backed by the Coalition for Epidemic Preparedness Innovations (CEPI), the vaccine project received $8.6 million in funding, enabling rapid progression from lab to human trials. Pending regulatory clearance, additional studies are being planned in Uganda in collaboration with the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene & Tropical Medicine’s Uganda Research Unit.

Implications for the Ongoing Outbreak

The Bundibugyo Ebola outbreak has become the third‑largest on record, with case numbers still climbing. An effective vaccine could dramatically curb transmission, relieve overstretched health systems, and protect vulnerable communities. The swift move to human testing underscores one of the fastest vaccine responses to an emerging infectious disease in recent history.